Doxylamine Succinate

CHEMBL1200392 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
388.5 g/mol
LogP
Phase
4

A succinate salt form of doxylamine used as a sleep aid and to treat pregnancy-related nausea. Like the parent compound, it exerts sedative and antiemetic effects through histamine receptor blockade.

น้ำหนักโมเลกุล

388.5000 g/mol

TPSA

100.00 Ų

ด้านการรักษา

กลไกการออกฤทธิ์

Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CN(C)CCOC(C)(c1ccccc1)c1ccccn1.O=C(O)CCC(=O)O

InChI

InChI=1S/C17H22N2O.C4H6O4/c1-17(20-14-13-19(2)3,15-9-5-4-6-10-15)16-11-7-8-12-18-16;5-3(6)1-2-4(7)8/h4-12H,13-14H2,1-3H3;1-2H2,(H,5,6)(H,7,8)

Molecular Formula

C21H28N2O5

HBD / HBA

2 / 7

พันธะที่หมุนได้

9

อะตอมหนัก

28

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

A succinate salt form of doxylamine used as a sleep aid and to treat pregnancy-related nausea. Like the parent compound, it exerts sedative and antiemetic effects through histamine receptor blockade.

Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.

Yes, Doxylamine Succinate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200392. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 11224. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.